In the most recent trading session, Boston Scientific (BSX) closed at $102.43, indicating a -0.65% shift from the previous trading day.
BSX posts solid Q1 sales growth in emerging markets, reinforcing their role in the company's long-term global strategy.
Boston Scientific is a global leader in medical devices, excelling in both MedSurg and Cardiovascular segments with consistent, industry-beating growth. Q1 2024 was a record quarter, with 21% YoY revenue growth, strong margins, and EPS beating expectations by $0.08. Organic growth and strategic acquisitions fuel BSX's expansion, supported by a diverse portfolio and active venture investments.
22 Jul 2025 (47 Days) Date | | - Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | 0.66 Cons. EPS | 0.7 EPS |
24 Oct 2024 Date | | 0.59 Cons. EPS | - EPS |
23 Oct 2024 Date | | 0.59 Cons. EPS | 0.63 EPS |
22 Jul 2025 (47 Days) Date | | - Cons. EPS | - EPS |
22 Apr 2025 Date | | - Cons. EPS | - EPS |
29 Jan 2025 Date | | 0.66 Cons. EPS | 0.7 EPS |
24 Oct 2024 Date | | 0.59 Cons. EPS | - EPS |
23 Oct 2024 Date | | 0.59 Cons. EPS | 0.63 EPS |
Medical - Devices Industry | Healthcare Sector | Mr. Michael F. Mahoney CEO | CXA Exchange | US1011371077 ISIN |
US Country | 53,000 Employees | - Last Dividend | 6 Nov 2003 Last Split | 18 May 1992 IPO Date |
Boston Scientific Corporation is a global developer, manufacturer, and marketer of medical devices used in a variety of interventional medical specialties. Having begun its operations in 1979, the company has grown to serve a diverse range of medical needs through its two primary segments: MedSurg and Cardiovascular. With its headquarters in Marlborough, Massachusetts, Boston Scientific is committed to improving patient health by providing cutting-edge solutions that address complex medical conditions and enhance the quality of life for patients worldwide.